Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Nectar Lifesciences Ltd (NECLIFE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532649 NSE: NECLIFE Pharmaceuticals & Drugs | Small Cap | Nectar Lifesciences Share Price
₹10.74 0.11 (1.03%)
As on 24-Aug'26 16:59
Nectar Lifesciences Ltd (NECLIFE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532649 NSE: NECLIFE Pharmaceuticals & Drugs | Small Cap | Nectar Lifesciences Share Price
₹10.74 0.11 (1.03%)
As on 24-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹209 Cr.
Current Price
₹10.7
52-Week Low / High
₹9 / 22
TTM EPS
₹0.9
TTM Sales
₹5 Cr.
Book Value per Share
₹29.3
P/E Ratio
12.54
Industry PE
53.2
Price to Book (P/B)
0.37
Lower than its 5-year historical median
Price to Sales (P/S)
41.64
Higher than its 5-year historical median
EV/EBITDA
-1.36
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-7.45%
Underperforms industry median
Return on Capital Employed (ROCE)
-4.75%
Underperforms industry median
Return on Assets (ROA)
-4.82%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-8291.43%
Asset Quality
Promoter Holding
51.84%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹549 Cr.
Equity
₹19.4 Cr.
Face Value
₹1
All Time Low / High
₹7.20 / 60.90
Check Before You Invest
Quality
Somewhat GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Nectar Lifesciences Ltd a good quality company?
Nectar Lifesciences Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Nectar Lifesciences Ltd performance compare with that of its Peers?
Revenue growth of Nectar Lifesciences Ltd vs industry peers?
Nectar Lifesciences Ltd revenue CAGR is -100.00%, compared to the industry median CAGR of 5.79%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Nectar Lifesciences Ltd?
Promoters hold 51.84% of the Nectar Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Nectar Lifesciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -11.1% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Nectar Lifesciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 9.7% | 9.1% | 10.3% | 8.2% | 1.4% | 5.8% | 2.6% | 6.7% | 0.6% | -4.8% | - |
| Value Creation Index ⓘ | -0.3 | -0.4 | -0.3 | -0.4 | -0.9 | -0.6 | -0.8 | -0.5 | -1.0 | -1.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 1,643 | 1,876 | 2,785 | 2,363 | 1,542 | 1,668 | 1,524 | 1,684 | 0 | 0 | 5 |
| Sales YoY Gr. | - | 14.1% | 48.5% | -15.2% | -34.8% | 8.2% | -8.7% | 10.5% | -100% | NA | - |
| Adj EPS ⓘ | 2.4 | 2.3 | 2.1 | 1.3 | -2.5 | 0.8 | -2.6 | -0.1 | -0.2 | -1.1 | 0.9 |
| YoY Gr. | - | -3.7% | -9% | -37.3% | -285.7% | NA | -406% | NA | NA | NA | - |
| BVPS (₹) ⓘ | 44.9 | 47.2 | 49.3 | 50.6 | 47.3 | 48.5 | 47.5 | 47.7 | 42.6 | 30 | 29.3 |
| Adj Net Profit ⓘ | 54.3 | 52.2 | 47.5 | 29.9 | -55.4 | 18.7 | -57.7 | -2 | -5.3 | -21.7 | 17 |
| Cash Flow from Ops. ⓘ | 199 | 65.1 | 239 | 286 | 21.3 | 95 | 133 | 225 | 169 | -417 | - |
| Debt/CF from Ops. ⓘ | 4.4 | 14.7 | 3.8 | 2.7 | 42.4 | 9.1 | 5.7 | 2.8 | 3.4 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -100% | -100% | -100% | NA | ||||
| Adj EPS ⓘ | -191.8% | NA | NA | NA | ||||
| BVPSⓘ | -4.4% | -8.7% | -14.2% | -29.7% | ||||
| Share Price | -11.3% | -19% | -25.4% | -29.5% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 5.5 | 5.1 | 4.4 | 2.7 | -5 | 1.7 | -5.4 | -0.2 | -0.5 | -2.8 | 2.9 |
| Op. Profit Mgn % ⓘ | 13.6 | 12.6 | 9.5 | 9.2 | 6.6 | 9.5 | 3.6 | 9 | 0 | 0 | -394.9 |
| Net Profit Mgn % ⓘ | 3.3 | 2.8 | 1.7 | 1.3 | -3.6 | 1.1 | -3.8 | -0.1 | 0 | 0 | 333.5 |
| Debt to Equity ⓘ | 0.9 | 0.9 | 0.8 | 0.7 | 0.9 | 0.8 | 0.7 | 0.6 | 0.6 | 0 | - |
| Working Cap Days ⓘ | 324 | 292 | 206 | 240 | 330 | 288 | 310 | 272 | 0 | 0 | 1,166 |
| Cash Conv. Cycle ⓘ | 153 | 133 | 104 | 115 | 132 | 108 | 126 | 109 | 0 | 0 | -2,043 |
Valuation of Nectar Lifesciences - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 100.00 | 100.00 | 100.00 | 99.60 | 99.60 | 99.60 | 98.77 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,643 | 1,876 | 2,785 | 2,363 | 1,542 | 1,668 | 1,524 | 1,684 | 0 | 0 |
| Operating Expenses ⓘ + | 1,419 | 1,639 | 2,521 | 2,145 | 1,440 | 1,509 | 1,469 | 1,533 | 0 | 61 |
| Operating Profit ⓘ | 224 | 236 | 264 | 218 | 102 | 159 | 55 | 152 | -0 | -61 |
| Operating Profit Margin (%) | 13.6% | 12.6% | 9.5% | 9.2% | 6.6% | 9.5% | 3.6% | 9.0% | - | - |
| Other Income ⓘ + | 23 | 6 | 6 | 4 | 11 | 11 | 53 | 27 | 10 | 11 |
| Interest ⓘ | 117 | 115 | 148 | 126 | 112 | 79 | 89 | 99 | 9 | 37 |
| Depreciation ⓘ | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 1 | 0 |
| Profit Before Tax ⓘ | 67 | 63 | 59 | 36 | -85 | 34 | -41 | 18 | 1 | -88 |
| Tax ⓘ | 12 | 10 | 11 | 6 | -12 | 9 | -18 | 13 | 0 | -31 |
| Profit After Tax | 55 | 52 | 47 | 30 | -73 | 25 | -22 | 5 | 1 | -57 |
| PAT Margin (%) | 3.4% | 2.8% | 1.7% | 1.3% | -4.7% | 1.5% | -1.5% | 0.3% | - | - |
| Adjusted EPS (₹) | 2.5 | 2.3 | 2.1 | 1.3 | -3.3 | 1.1 | -1.0 | 0.2 | 0.0 | -3.0 |
| Dividend Payout Ratio (%) | 2% | 2.20% | 2.40% | 3.70% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 1,007 | 1,059 | 1,105 | 1,135 | 1,061 | 1,087 | 1,065 | 1,069 | 956 | 582 | |
| Debt + | 794 | 854 | 802 | 741 | 840 | 794 | 685 | 553 | 500 | 0 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 528 | 539 | 483 | 527 | 342 | 377 | 319 | 420 | 438 | 0 | |
| Others Liabilities ⓘ | 252 | 272 | 315 | 229 | 132 | 130 | 100 | 142 | 98 | -194 | |
| Total Liabilities ⓘ | 2,581 | 2,724 | 2,704 | 2,632 | 2,375 | 2,387 | 2,169 | 2,184 | 1,992 | 388 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 | 3 | |
| CWIP ⓘ | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 | 0 | |
| Investments ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | |
| Inventories | 854 | 859 | 915 | 975 | 587 | 660 | 673 | 709 | 690 | 0 | |
| Trade Receivables | 500 | 612 | 561 | 397 | 375 | 447 | 280 | 379 | 345 | 0 | |
| Cash Equivalents | 13 | 9 | 21 | 21 | 25 | 18 | 18 | 20 | 19 | 108 | |
| Others Assets ⓘ | 229 | 290 | 282 | 338 | 516 | 454 | 459 | 366 | 247 | 263 | |
| Total Assets ⓘ | 2,581 | 2,724 | 2,704 | 2,632 | 2,375 | 2,387 | 2,169 | 2,184 | 1,992 | 388 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 199 | 65 | 239 | 286 | 21 | 95 | 133 | 225 | 169 | -417 |
| Cash Flow From Investing Activity ⓘ + | -18 | -29 | -26 | -33 | -29 | 17 | 52 | -17 | -42 | 1,205 |
| Cash Flow From Financing Activity ⓘ + | -204 | -40 | -201 | -252 | 11 | -119 | -186 | -205 | -128 | -699 |
| Net Cash Flow ⓘ | -24 | -4 | 12 | 1 | 4 | -8 | -0 | 2 | -1 | 89 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 5.62 | 5.05 | 4.38 | 2.68 | -6.66 | 2.36 | -2.09 | 0.47 | 0.07 | -7.45 |
| ROCE (%) | 9.71 | 9.12 | 10.28 | 8.24 | 1.41 | 5.79 | 2.58 | 6.68 | 0.59 | -4.75 |
| Asset Turnover Ratio | 0.68 | 0.79 | 1.15 | 0.99 | 0.7 | 0.81 | 0.77 | 0.88 | 0 | 0 |
| PAT to CFO Conversion(x) | 3.62 | 1.25 | 5.09 | 9.53 | N/A | 3.8 | N/A | 45 | 169 | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 103.90 | 97 | 68.80 | 66.30 | 79.90 | 77.90 | 75.90 | 62.40 | 0 | 0 |
| Inventory Days | 176.90 | 149.50 | 103.90 | 130.70 | 161.80 | 118.20 | 139.20 | 130.90 | 0 | 0 |
| Payable Days | 162.10 | 142.60 | 84 | 99.20 | 137.30 | 107.30 | 109.50 | 112.10 | 0 | 0 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Nectar Lifesciences Ltd FAQs
The current trading price of Nectar Lifesciences on 24-Aug-2026 16:59 is ₹10.74.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Aug-2026 the market cap of Nectar Lifesciences stood at ₹208.6 Cr
The latest P/E ratio of Nectar Lifesciences as of 23-Aug-2026 is 12.54.
The latest P/B ratio of Nectar Lifesciences as of 23-Aug-2026 is 0.37.
The 52-week high of Nectar Lifesciences is ₹22.49 and the 52-week low is ₹9.20.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nectar Lifesciences is ₹5.01 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Nectar Lifesciences Ltd is a average quality company.
The key valuation ratios of Nectar Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Nectar Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Nectar Lifesciences Ltd
Nectar Lifesciences (Nectar) is a research-driven, leading manufacturer of Active Pharmaceutical Ingredients (API), intermediates as well as Finished dosage forms offering largest segment of anti-infectives namely Cephalosporins. Nectar has proven to be a reliable CMO (Contract Manufacturing Organization) to global pharma innovators. Nectar has leading global capacities in Cephalosporin antibiotics such as Cefixime, Cefuroxime Axetil Amorphous, Cefuroxime Axetil Crystalline, Cefotaxime Sodium, Ceftriaxone Sodium.
The company is the world’s leading producer of Cefixime Trihydrate, Cefuroxime Axetil, Cefpodoxime Proxetil and Sterile APIs. All of the company’s plants can be converted to multi-purpose plants based on product basket requirement.
Business area of the company
Nectar is a global pharmaceutical company specializing in Cephalosporins.
Products
Oral Cephalosporins:
- Cefixime
- Cefurozime Axetil Crystalline
- Cefuroxime Axetil Amorphous
- Cedpodoxime Proxetil
- Cefprozil
- Cefdinir
Sterile Cephalosporins:
- Cefotaxime Sodium
- Ceftriaxone Sodium
- Cefuroxime Sodium
- Cefazolin Sodium
- Ceftazidime pentahydrate
- Cefepime +Arginine
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
